TY - JOUR
T1 - Eμ-TCL1 adoptive transfer mouse model of chronic lymphocytic leukemia
AU - Fernandez Botana, Iria
AU - Gonder, Susanne
AU - Klapp, Vanessa
AU - Moussay, Etienne
AU - Paggetti, Jerome
N1 - Acknowledgments
This work was supported by grants from the Luxembourg National Research Fund (FNR) and Fondation Cancer to V.K., E.M. and J.P. (PRIDE19/14254520/i2TRON, C20/BM/14582635, and C20/BM/14592342), and from FNRS-Télévie to S.G. (7.4502.19, 7.6604.21) and I.F.B. (7.4529.19, 7.6603.21).
Publisher Copyright:
© 2024 Elsevier Inc.
PY - 2024/6/14
Y1 - 2024/6/14
N2 - Despite being the most common adult leukemia in the western world, Chronic Lymphocytic Leukemia (CLL) remains a life-threatening and incurable disease. Efforts to develop new treatments are highly dependent on the availability of appropriate mouse models for pre-clinical testing. The Eμ-TCL1 mouse model is the most established pre-clinical approach to study CLL pathobiology and response to treatment, backed by numerous studies highlighting its resemblance to the most aggressive form of this malignancy. In contrast to the transgenic Eμ-TCL1 model, employing the adoptive transfer of Eμ-TCL1-derived splenocytes in immunocompetent C57BL/6 mice results in a comparably rapid (e.g., leukemic development within weeks compared to months in the transgenic model) and reliable model mimicking CLL. In this chapter, we would like to provide readers with a thoroughly optimized, detailed, and comprehensive protocol to use the adoptive transfer Eμ-TCL1 model in their research.
AB - Despite being the most common adult leukemia in the western world, Chronic Lymphocytic Leukemia (CLL) remains a life-threatening and incurable disease. Efforts to develop new treatments are highly dependent on the availability of appropriate mouse models for pre-clinical testing. The Eμ-TCL1 mouse model is the most established pre-clinical approach to study CLL pathobiology and response to treatment, backed by numerous studies highlighting its resemblance to the most aggressive form of this malignancy. In contrast to the transgenic Eμ-TCL1 model, employing the adoptive transfer of Eμ-TCL1-derived splenocytes in immunocompetent C57BL/6 mice results in a comparably rapid (e.g., leukemic development within weeks compared to months in the transgenic model) and reliable model mimicking CLL. In this chapter, we would like to provide readers with a thoroughly optimized, detailed, and comprehensive protocol to use the adoptive transfer Eμ-TCL1 model in their research.
KW - Chemotherapy
KW - CLL pathogenesis
KW - Immunotherapy
KW - Splenomegaly
UR - http://www.scopus.com/inward/record.url?scp=85190822799&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/38880520/
U2 - 10.1016/bs.mcb.2024.03.012
DO - 10.1016/bs.mcb.2024.03.012
M3 - Article
AN - SCOPUS:85190822799
SN - 0091-679X
VL - 188
SP - 109
EP - 129
JO - Methods in Cell Biology
JF - Methods in Cell Biology
ER -